Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia
|ClinicalTrials.gov Identifier: NCT00001521|
Recruitment Status : Completed
First Posted : November 4, 1999
Last Update Posted : October 8, 2018
This study was developed to determine if a combination of four drugs (flutamide, testolactone, reduced hydrocortisone dose, and fludrocortisone) can normalize growth in children with congenital adrenal hyperplasia.
The study will take 60 children, boys and girls and divide them into 2 groups based on the medications given. Group one will receive the new four- drug combination. Group two will receive the standard treatment for congenital adrenal hyperplasia (hydrocortisone and fludrocortisone).
The boys in group one will take the medication until the age of 14 at which time they will stop taking the four drug combination and begin receiving the standard treatment for congenital adrenal hyperplasia. Girls in group one will take the four drug combination until the age of 13, at which time they will stop and begin receiving the standard treatment for congenital adrenal hyperplasia plus flutamide. Flutamide will be given to the girls until six months after their first menstrual period.
All of the children will be followed until they reach their final adult height. The effectiveness of the treatment will be determined by measuring the patient's adult height, body mass index, and bone density. <TAB>...
|Condition or disease||Intervention/treatment||Phase|
|Congenital Adrenal Hyperplasia Growth Disorder||Drug: Flutamide and Testolactone Drug: Deslorelin||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||62 participants|
|Official Title:||An Open, Randomized, Long-Term Clinical Trial of Flutamide, Testolactone, and Reduced Hydrocortisone Dose vs. Conventional Treatment of Children With Congenital Adrenal Hyperplasia|
|Study Start Date :||February 2, 1996|
|Actual Study Completion Date :||January 11, 2017|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00001521
|United States, Maryland|
|National Institutes of Health Clinical Center, 9000 Rockville Pike|
|Bethesda, Maryland, United States, 20892|
|Principal Investigator:||Deborah P Merke, M.D.||National Institutes of Health Clinical Center (CC)|